• Xiu-Yun Song
  • Ling-Lei Kong
  • Nai-Hong ChenEmail author


Indirubin comes from Indigofera tinctoria L., Baphicacanthus cusia Brem., Isatis tinctoria L., and Couroupita guianensis Aubl. The indirubin has been artificially synthesized. Indirubin has the effects of anti-inflammatory, antibacterial, detoxification, enhancing immune function, and has anticancer. Indirubin is used for the therapy of chronic myelocytic leukemia in clinical. It has the advantages of reliable clinical curative effect, small side effects, and no significant inhibitory effect on the bone marrow. Indirubin is an effective ingredient of medicine. Therefore, indirubin and its derivatives will become a new direction of research in the field of anticancer drugs.


Indirubin Chronic myeloid leukemia Cancer 


  1. 1.
    American Chemical Society. Chemical abstracts of the United States. Chemical abstracts of the United States Service, 1998.Google Scholar
  2. 2.
    Tu X. Study on the synthesis of natural products of indirubin and three phenol derivatives. Master’s thesis of Northwestern University. 2010.Google Scholar
  3. 3.
    Chen H, Sun J. Research progress of Folium Isatidis. China Pharm. 2004;13(8):79–80.Google Scholar
  4. 4.
    Wu J, Ge Z, Gao Y, Zhang L. Study on the inhibitory effect of indirubin on tumor cells and the related mechanisms. Tianjin Tradit Chin Med. 2008;1:55–8.Google Scholar
  5. 5.
    Hoessel R, Leclerc S, Endicott JA, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol. 1999;1(1):60–7.CrossRefGoogle Scholar
  6. 6.
    Xiao Z, Hao Y, Liu B, Qian L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk Lymphoma. 2002;43(9):1763–8.CrossRefGoogle Scholar
  7. 7.
    Nam S, Scuto A, Yang F, et al. Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling. Mol Oncol. 2012;6(3):276–83.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. and People's Medical Publishing House, PR of China 2018

Authors and Affiliations

  1. 1.Institute of Materia MedicaChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina
  2. 2.Beijing Key Laboratory of Drug Targets Identification and Drug Screening, Centre for Pharmaceutical ScreeningInstitute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Personalised recommendations